New platform integrates epigenetic and transcriptomic analysis in a unified workflow, addressing key challenges in single-cell multi-omics research.

LONDON, UK – SeekGene, a biotechnology company specializing in single-cell technology platforms, announced the launch of its novel high-throughput single-cell DNA methylation and RNA multi-omics solution at the Festival of Genomics & BioData 2026. The solution aims to simplify integrated epigenetic and transcriptomic analysis at single-cell resolution, enables the simultaneous profiling of RNA transcriptomes, immune repertoires (TCR/BCR, for immune cells), and genome-wide DNA methylation signals (5mC/5hmC) from the same single cell or nucleus. By capturing multiple molecular layers within a unified workflow, the platform is designed to address persistent challenges in single-cell multi-omics studies, including complex experimental setups, high sample consumption, and difficulties in aligning data generated from separate assays.

Integration Challenges in Single-Cell Research

As single-cell research increasingly expands toward multi-omics and large-scale study designs, researchers often rely on parallel workflows to analyze transcriptional, epigenetic, and immune repertoire information. These approaches typically require separate library preparation and sequencing strategies, increasing cost, time, and batch variability. According to SeekGene, the new solution was developed to provide a unified experimental framework that allows multiple molecular modalities to be captured from the same cell, supporting more direct analyses of how epigenetic states relate to gene expression and cellular function.

Key Technical Features

The SeekOne™ DD multi-omics solution employs a unified molecular tagging and library construction strategy to generate matched RNA expression profiles, immune receptor sequences, and genome-wide DNA methylation maps (5mC/5hmC) at the single-cell level. This direct correspondence across molecular layers helps reduce variability introduced by separate assays and supports more consistent downstream data integration.

Designed for high-throughput applications, each channel can process up to approximately 12,000 cells, with a single run supporting between one and eight channels depending on experimental design. The system is compatible with fresh or frozen tissues and supports both single-cell and single-nucleus workflows, allowing flexibility across a range of sample types, including immune, tumor, and complex tissue samples.

SeekGene notes that, when targeting comparable data quality, the solution requires lower overall sequencing depth than traditional low- to mid-throughput single-cell DNA methylation methods, helping to reduce sequencing costs.

Research Applications

The platform is expected to support research across multiple areas. In Human Cell Atlas–related efforts, the simultaneous acquisition of transcriptomic and epigenetic data can aid cell type annotation and the construction of high-resolution cellular reference maps. In developmental biology and aging research, the approach enables joint analysis of DNA methylation dynamics and gene expression changes at single-cell resolution.

In cancer research, copy number variation (CNV) signals inferred from DNA methylation data can be analyzed alongside immune cell RNA expression and immune repertoire profiles, supporting studies of tumor clonal architecture, evolutionary dynamics, and tumor immune microenvironments. More broadly, the platform provides a framework for investigating complex regulatory relationships between DNA methylation and gene expression in studies of cell fate decisions and differentiation.

More Information

For detailed technical specifications, example datasets, and information on product trials for the SeekOne™ DD Single-Cell DNA Methylation and RNA Multi-omics Solution, please visit www.seekgene.com or via info@seekgene.com.

About SeekGene

SeekGene advances the frontiers of single-cell analysis through innovative technology development. The company’s integrated single-cell multi-omics platforms, which cover transcriptomics, epigenomics, and spatial omics, empower the global research community to gain deeper biological and disease insights. Recognized for their impact, these technologies have been adopted by over 1,000 research institutions worldwide, with supporting research published in leading journals such as Cell, Science, and Nature.